Post-Graduate Program in Rehabilitation Sciences, Laboratory of Phototherapy and Innovative Technologies in Health (LaPIT), Nove de Julho University, São Paulo, Brazil.
Post-Graduate Program in Rehabilitation Sciences, Laboratory of Phototherapy and Innovative Technologies in Health (LaPIT), Nove de Julho University, São Paulo, Brazil -
Eur J Phys Rehabil Med. 2023 Dec;59(6):754-762. doi: 10.23736/S1973-9087.23.07928-5. Epub 2023 Oct 17.
Fibromyalgia is a syndrome characterized by generalized chronic pain and tenderness in specific areas. Photobiomodulation therapy (PBMT) using low-level laser therapy and/or light emitting diode therapy is an electrophysical agent that can be used alone or together with a static magnetic field (PBMT-sMF) to promote analgesia in several health conditions. Little evidence exists regarding the effects of using PBMT and PBMT-sMF in patients with fibromyalgia; this evidence is conflicting.
We aimed to investigate the effects of using PBMT-sMF versus a placebo on reduction of the degree-of-pain rating, impact of fibromyalgia, pain intensity, and satisfaction with treatment in patients with fibromyalgia.
A prospectively registered, monocentric, randomized placebo-controlled trial, with blinding of patients, therapists, and assessors, was performed.
The study was conducted at the Laboratory of Phototherapy and Innovative Technologies in Health (LaPIT) in Brazil, between March and October 2020.
Ninety female patients with fibromyalgia were randomized to undergo either PBMT-sMF (N.=45) or placebo (N.=45) treatment.
Patients from both groups received nine treatment sessions, three times a week, for 3 weeks. Clinical outcomes were collected at baseline, the end of treatment, and at the follow-up appointment 4 weeks post-treatment. The primary outcome was the degree-of-pain rating, measured by the reduction of the tender point count.
A decrease in the degree-of-pain rating was observed in patients allocated to the PBMT-sMF group, decreasing the number of tender points when compared to placebo group at the end of treatment (P<0.0001) and at the follow-up assessment (P<0.0001). Patients did not report any adverse events.
PBMT-sMF is superior to placebo, supporting its use in patients with fibromyalgia.
PBMT-sMF might be considered an important adjuvant to the treatment regimens of patients with fibromyalgia.
纤维肌痛是一种以全身慢性疼痛和特定区域压痛为特征的综合征。光生物调节疗法(PBMT)使用低水平激光疗法和/或发光二极管疗法是一种物理电疗,可以单独使用或与静磁场(PBMT-sMF)一起用于促进多种健康状况的镇痛。关于纤维肌痛患者使用 PBMT 和 PBMT-sMF 的效果证据有限,而且这些证据相互矛盾。
我们旨在研究 PBMT-sMF 与安慰剂相比对减轻纤维肌痛患者疼痛评分程度、纤维肌痛影响、疼痛强度和治疗满意度的影响。
这是一项前瞻性注册、单中心、随机安慰剂对照试验,对患者、治疗师和评估者进行了盲法。
该研究在巴西的光疗和创新技术实验室(LaPIT)进行,时间为 2020 年 3 月至 10 月。
90 名纤维肌痛女性患者被随机分为 PBMT-sMF 组(N=45)或安慰剂组(N=45)。
两组患者均接受 9 次治疗,每周 3 次,持续 3 周。临床结果在基线、治疗结束时和治疗结束后 4 周的随访时收集。主要结局是疼痛评分程度,通过压痛点数的减少来衡量。
与安慰剂组相比,接受 PBMT-sMF 治疗的患者疼痛评分程度下降,治疗结束时压痛点数减少(P<0.0001),随访时也减少(P<0.0001)。患者未报告任何不良事件。
PBMT-sMF 优于安慰剂,支持其在纤维肌痛患者中的应用。
PBMT-sMF 可能被视为纤维肌痛患者治疗方案的重要辅助手段。